{
    "clinical_study": {
        "@rank": "40345", 
        "acronym": "EARTH", 
        "arm_group": [
            {
                "arm_group_label": "Standard Therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Risk factor control Diet Exercise"
            }, 
            {
                "arm_group_label": "Rosuvastatin therapy", 
                "arm_group_type": "Experimental", 
                "description": "Risk factor control Rosuvastatin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare standard therapy (risk factor control, life style\n      modification) versus standard therapy plus low-dose rosuvastatin therapy (5mg/day) on\n      progression of coronary atherosclerosis in statin naive individuals who have mild CAD\n      (nonobstructive coronary atherosclerotic plaques) and normal LDL (low-density lipoprotein)\n      cholesterol levels(\u3008130mg/dl)."
        }, 
        "brief_title": "EARly Prevention of aTHeroma Progression", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Arteriosclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Arteriosclerosis", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Plaque, Atherosclerotic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women at least 35 years of age\n\n          -  Mild CAD (nonobstructive coronary atherosclerotic plaques, lumen narrowing <50%) and\n             CAC score <300 in at least one segment of proximal or mid-portion of major epicardial\n             coronary arteries\n\n          -  LDL cholesterol <130mg/dl\n\n        Exclusion Criteria:\n\n          -  History of stable angina, or acute coronary syndrome\n\n          -  History of transient ischemic attack, or stroke\n\n          -  Chronic kidney disease (eGFR< 60ml/min)\n\n          -  Diabetes mellitus with microvascular complications or insulin therapy\n\n          -  Hypertriglyceridemia (triglyceride >500mg/dl)\n\n          -  Any statin therapy in the past 4 weeks\n\n          -  Planned cardiac surgery or planned major non-cardiac surgery within 6 months.\n\n          -  Chronic disease requiring treatment with oral, intravenous, or intra-articular\n             corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).\n\n          -  A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in\n             the past 3 years or current treatment for the active cancer.\n\n          -  Any clinically significant abnormality identified at the screening visit, physical\n             examination, laboratory tests, or electrocardiogram which, in the judgment of the\n             Investigator, would preclude safe completion of the study.\n\n          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation\n             (ALT or AST > 3 times upper limit of normal).\n\n          -  History of adult asthma manifested by bronchospasm in the past 6 months, or currently\n             taking regular anti-asthmatic medication(s).\n\n          -  Unwillingness or inability to comply with the procedures described in this protocol.\n\n          -  Positive pregnancy test (all female subjects of childbearing potential must have a\n             urine \u00df-human chorionic gonadotropin(hCG) pregnancy test performed at Screening and/\n             or within 7 days prior to randomization) or is known to be pregnant or lactating.\n\n          -  Hypersensitivity to Crestor\n\n          -  Skeletal muscle disease\n\n          -  Combination use with cyclosporine\n\n          -  Galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption\n\n          -  Combination use of protease inhibitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "320", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105623", 
            "org_study_id": "AMCCV2013-09"
        }, 
        "intervention": [
            {
                "arm_group_label": "Standard Therapy", 
                "description": "Risk factor control Diet Exercise for 24months", 
                "intervention_name": "Standard Therapy", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": "Rosuvastatin therapy", 
                "description": "Risk factor control rosuvastatin 5mg/day for 24months", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Coronary Arteriosclerosis", 
            "rosuvastatin"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "contact": {
                "email": "cheolwlee@amc.seoul.kr", 
                "last_name": "Cheol-whan Lee, MD"
            }, 
            "contact_backup": {
                "email": "cvcrc5@amc.seoul.kr", 
                "last_name": "Jung-hee Ham, Research coordinator"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Cheol-whan Lee, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "EARly Prevention of aTHeroma Progression", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percent change in total atheroma volume(TAV) at region of interest defined as(TAV at 24 months-TAV at baseline)/(TAV at baseline)x 100", 
            "measure": "Percent change in total atheroma volume(TAV)", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105623"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "CHEOL WHAN LEE, M.D., Ph.D", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in PAV(Percent atheroma volume) at region of interest(PAV at 24months-PAV at baseline)", 
                "measure": "Change in PAV(Percent atheroma volume) at region of interest", 
                "safety_issue": "No", 
                "time_frame": "2years"
            }, 
            {
                "description": "Sum of TAV in all coronary segments", 
                "measure": "Change in overall TAV", 
                "safety_issue": "No", 
                "time_frame": "2years"
            }, 
            {
                "description": "TAV at 24months-TAV at baseline", 
                "measure": "Change in TAV at region of interest", 
                "safety_issue": "No", 
                "time_frame": "2years"
            }, 
            {
                "description": "overall CAC score at 24months-overall CAC score at baseline", 
                "measure": "Change in overall CAC(coronary artery calcification) score", 
                "safety_issue": "No", 
                "time_frame": "2years"
            }, 
            {
                "measure": "Change in number of segment of any coronary atherosclerotic plaques", 
                "safety_issue": "No", 
                "time_frame": "2years"
            }, 
            {
                "measure": "Percent change from baseline in lipid levels", 
                "safety_issue": "No", 
                "time_frame": "2years"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "CHEOL WHAN LEE, M.D., Ph.D", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}